Drug General Information (ID: DDIFB1YL28)
Drug Name			Amikacin (liposome)		Drug Info		Amphotericin B (lipid complex)		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Antifungal Agents
Structure

Mechanism of Amikacin (liposome)-Amphotericin B (lipid complex) Interaction (Severity Level: Moderate)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Amikacin (liposome)				Amphotericin B (lipid complex)
Mechanism		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 1
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Amikacin (liposome) and Amphotericin B (lipid complex)

Recommended Action
Management		Just before the start and just before the end of each amphotericin infusion, hydration of the patient with 500 mL of normal saline may be helpful. The patient's renal function should be monitored frequently during therapy.

References
1	Churchill DN, Seely J "Nephrotoxicity associated with combined gentamicin - amphotericin B therapy." Nephron 19 (1977): 176-81. [PMID: 268496]
2	Product Information. Abelcet (amphotericin B). Liposome Company Inc, The, Princeton, NJ.
3	Product Information. Arikayce (amikacin liposome). Insmed Incorporated, Bridgewater, NJ.